Priorities for Rural Lymphoma Survivors: A Qualitative Study

ConclusionThese findings suggest that targeted research and interventions are necessary to address the specific needs of rural lymphoma patients and survivors. To address the disparity in health outcomes within rural populations, health care professionals and investigators can utilize these data to engage rural patients in treatment decision-making and research planning.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research

Related Links:

ConclusionsPCPs report several barriers in providing care to hematologic malignancy/HCT survivors. Clinical experience with this patient population is associated with greater confidence in providing survivorship care. Several barriers identified by PCPs in providing survivorship care to hematologic malignancy/HCT survivors are potentially addressable by education, clinical decision support tools and guidelines, enhancing clinical experience, and care coordination with hematologist-oncologists.
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Giulia Gabrielli, Alessandro Broccoli, Cinzia Pellegrini, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
We describe three clinical scenarios in which CAR T- cell immunotherapy interfered with HIV-1 testing including: (1) routine infectious disease screening prior to stem cell transplantation in a 16-year-old female with B-cell acute lymphoblastic leukemia, status post CAR T- cell treatment (2) routine infectious disease screening prior to 2nd CAR T- cell collection in a 65-year-old male with diffuse large B-cell lymphoma who failed initial CAR T- cell treatment and (3) routine infectious risk assessment following an occupational health exposure from a 58 -year-old male with multiple myeloma, status post CAR T- cell treatment...
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: J Clin Microbiol Source Type: research
Kim De Veirman AXL belongs to the TAM (TYRO3, AXL, and MERTK) receptor family, a unique subfamily of the receptor tyrosine kinases. Their common ligand is growth arrest-specific protein 6 (GAS6). The GAS6/TAM signaling pathway regulates many important cell processes and plays an essential role in immunity, hemostasis, and erythropoiesis. In cancer, AXL overexpression and activation has been associated with cell proliferation, chemotherapy resistance, tumor angiogenesis, invasion, and metastasis; and has been correlated with a poor prognosis. In hematological malignancies, the expression and function of AXL is highly...
Source: Cancers - Category: Cancer & Oncology Authors: Tags: Review Source Type: research
CONCLUSION: In a real-world setting, the QLQ-C30 summary score has a strong prognostic value for overall survival for a number of populations of patients with cancer above and beyond that provided by clinical and sociodemographic variables. The QLQ-C30 summary score appears to have more prognostic value than the global QoL, physical functioning, or any other scale within the QLQ-C30. IMPLICATIONS FOR PRACTICE: The finding that health-related quality of life provides distinct prognostic information beyond known sociodemographic and clinical measures, not only around cancer diagnosis (baseline) but also at follow-up, ha...
Source: The Oncologist - Category: Cancer & Oncology Authors: Tags: Oncologist Source Type: research
CONCLUSION: All tested biosimilars demonstrated similar effectiveness and safety profiles in patients with hematological tumors undergoing PBSC mobilization; therefore, they can be used interchangeably. PMID: 31663634 [PubMed - as supplied by publisher]
Source: Clinical Lymphoma and Myeloma - Category: Cancer & Oncology Authors: Tags: J Clin Apher Source Type: research
Publication date: Available online 21 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Luo Huang, Yongzhong Wu, Ying Wang, Yue Xie, Furong Wu, Shujie Li, Zhongguo Liang, Xiaodong ZhuAbstractThe aim of this study is to develop a prognostic nomogram for early stage extranodal NK/T-cell lymphoma, nasal-type (ENKL) treated with high-dose radiotherapy (RT). A total of 81 patients at two cancer centers with stage I to IIE ENKL who received chemotherapy (CT) and high-dose RT were retrospectively analyzed. The 5-year OS rate and PFS were 64.7% and 57.5% respectively for the entire group. The development of the ...
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
Publication date: Available online 21 October 2019Source: Clinical Lymphoma Myeloma and LeukemiaAuthor(s): Giulia Gabrielli, Alessandro Broccoli, Cinzia Pellegrini, Lisa Argnani, Michele Cavo, Pier Luigi Zinzani
Source: Clinical Lymphoma Myeloma and Leukemia - Category: Cancer & Oncology Source Type: research
The aim of this study is to develop a prognostic nomogram for early stage extranodal NK/T-cell lymphoma, nasal-type (ENKL) treated with high-dose radiotherapy (RT). A total of 81 patients at two cancer centers with stage I to IIE ENKL who received chemotherapy (CT) and high-dose RT were retrospectively analyzed. The 5-year OS rate and PFS were 64.7% and 57.5% respectively for the entire group. The development of the nomogram was based on the Cox proportional hazards model. We have implemented the concordance index (C-index) and performed a calibration curve to determine its predictive and discriminatory capacity and compar...
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Original Study Source Type: research
We reported on a 54-year-old patient with a diagnosis of grade 2 follicular lymphoma (FL) and concomitant renal cancer. After the nephrectomy, the patient underwent two lines of chemoimmunotherapy, autologous stem cell transplant, obtained a complete response with idelalisib and underwent an allogeneic transplant (alloSCT).
Source: Clinical Lymphoma, Myeloma and Leukemia - Category: Hematology Authors: Tags: Case Report Source Type: research
More News: Alternative and Complementary Therapies | Cancer | Cancer & Oncology | Complementary Medicine | Conferences | Education | Georgia Health | Health Management | Leukemia | Lymphoma | Myeloma | Rural Health | Study | Universities & Medical Training